Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": The CASA randomized trial

被引：41

作者：

Crivellari, Diana ^{[1
]}

Gray, Kathryn P. ^{[2
,3
]}

Dellapasqua, Silvia ^{[4
]}

Puglisi, Fabio ^{[5
]}

Ribi, Karin ^{[6
]}

Price, Karen N. ^{[7
,8
]}

Lang, Istvan ^{[9
]}

Gianni, Lorenzo ^{[10
,11
]}

Spazzapan, Simon ^{[1
]}

Pinotti, Graziella ^{[12
,13
]}

Luethi, Jean-Marc ^{[14
]}

Gelber, Richard D. ^{[2
,3
,15
]}

Regan, Meredith M. ^{[2
,15
]}

Colleoni, Marco ^{[4
]}

Castiglione-Gertsch, Monica ^{[16
]}

Maibach, Rudolf ^{[8
,17
]}

Rabaglio, Manuela ^{[17
,18
]}

Coates, Alan S. ^{[19
,20
]}

Goldhirsch, Aron ^{[21
]}

机构：

[1] Ctr Riferimento Oncol, I-33081 Aviano, Italy

[2] Dana Farber Canc Inst, Dept Biostat & Computat Biol, IBCSG, Ctr Stat, Boston, MA 02115 USA

[3] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA

[4] European Inst Oncol, Dept Med, Res Unit Med Senol, Milan, Italy

[5] Univ Udine, Dept Med & Biol Sci, I-33100 Udine, Italy

[6] Int Breast Canc Study Grp, Coordinating Ctr, Qual Life Off, Bern, Switzerland

[7] Int Breast Canc Study Grp, Ctr Stat, Boston, MA USA

[8] Frontier Sci & Technol Res Fdn Inc, Boston, MA USA

[9] Natl Inst Oncol, Budapest, Hungary

[10] Osped Infermi Rimini, Dept Oncol, Rimini, Italy

[11] Ist Sci Romagnolo Studio & Cura Tumori, Rimini, Italy

[12] Osped Circolo Varese, Varese, Italy

[13] Fdn Macchi, Varese, Italy

[14] Spital SIS AG, Thun, Switzerland

[15] Harvard Univ, Sch Med, Boston, MA USA

[16] Univ Geneva, Dept Med Hop, Unite Oncogynecol Med, Geneva, Switzerland

[17] Int Breast Canc Study Grp, Coordinating Ctr, Bern, Switzerland

[18] Univ Bern, Inselspital, Dept Med Oncol, CH-3010 Bern, Switzerland

[19] Int Breast Canc Study Grp, Sydney, NSW, Australia

[20] Univ Sydney, Sydney, NSW 2006, Australia

[21] European Inst Oncol, Dept Med, Milan, Italy

来源：

BREAST | 2013年 / 22卷 / 02期

关键词：

Adjuvant treatment; Endocrine nonresponsive; Chemotherapy; Pegylated liposomal doxorubicin; Elderly; Breast cancer; QUALITY-OF-LIFE; ELDERLY-PATIENTS PTS; INTERNATIONAL SOCIETY; CAPECITABINE X; IBANDRONATE I; MINI-COG; PHARMACOKINETICS; CYCLOPHOSPHAMIDE; RECOMMENDATIONS; METHOTREXATE;

D O I：

10.1016/j.breast.2013.01.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

There is no optimal treatment for breast cancers lacking estrogen (ER) and progesterone (PgR) receptors in elderly women with co-morbidities that prevent use of "standard chemotherapy regimens" such as AC or CMF. The CASA trial studied pegylated liposomal doxorubicin (PLD) and low dose, metronomic cyclophosphamide methotrexate (CM) for older (>65), vulnerable women with operable, ER and PgR-negative breast cancer. After two years the trial closed early, due to slow and inadequate accrual, with 77 patients (38:PLD, 36:CM, 3:nil). Sixty-eight percent completed PLD; 83% completed CM (both 16 weeks). Patients on PLD reported worse quality of life, cognitive and physical functioning than non-PLD regimens (primarily CM). At a median follow-up of 42 months, 81% of randomized patients remained free of any breast cancer recurrence. Based on our limited experience, PLD and CM may be reasonable options for further study for elderly vulnerable patients with endocrine nonresponsive breast cancer. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：130 / 137

页数：8

共 50 条

[1] Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients
Coltelli, Luigi
Fontana, Andrea
Lucchesi, Sara
Ginocchi, Laura
Bocci, Guido
Filidei, Mario
Scalese, Marco
Arrighi, Giada
Finale, Chiara
Marcucci, Lorenzo
Goletti, Orlando
Salvadori, Barbara
Ferrarini, Ilaria
Bona, Eleonora
Falcone, Alfredo
Allegrini, Giacomo
BREAST, 2017, 31 : 186 - 191
[2] Adjuvant Chemotherapy in Older Women With Breast Cancer: Who and What?
Muss, Hyman B.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (19) : 1996 - 2000
[3] Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in older metastatic breast cancer patients
Kurtz, J. E.
Rousseau, F.
Meyer, N.
Delozier, T.
Serin, D.
Nabet, M.
Djafari, L.
Dufour, P.
ONCOLOGY, 2007, 73 (3-4) : 210 - 214
[4] Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study
Zhang, Jin
Jiang, Hongchuan
Zhang, Jian
Bao, Guoqiang
Zhang, Guoqiang
Wang, Haibo
Wang, Xi
BMC CANCER, 2021, 21 (01)
[5] Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study
Jin Zhang
Hongchuan Jiang
Jian Zhang
Guoqiang Bao
Guoqiang Zhang
Haibo Wang
Xi Wang
BMC Cancer, 21
[6] Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial
Perrone, F.
Nuzzo, F.
Di Rella, F.
Gravina, A.
Iodice, G.
Labonia, V.
Landi, G.
Pacilio, C.
Rossi, E.
De Laurentiis, M.
D'Aiuto, M.
Botti, G.
Forestieri, V.
Lauria, R.
De Placido, S.
Tinessa, V.
Daniele, B.
Gori, S.
Colantuoni, G.
Barni, S.
Riccardi, F.
De Maio, E.
Montanino, A.
Morabito, A.
Daniele, G.
Di Maio, M.
Piccirillo, M. C.
Signoriello, S.
Gallo, C.
de Matteis, A.
ANNALS OF ONCOLOGY, 2015, 26 (04) : 675 - 682
[7] Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study
Coltelli, Luigi
Finale, Chiara
Musettini, Gianna
Fontana, Andrea
Barletta, Maria Teresa
Lucarini, Alessandra Renata
Fabiani, Iacopo
Scalese, Marco
Bocci, Guido
Masini, Luna Chiara
Soria, Giulia
Cupini, Samanta
Arrighi, Giada
Barbara, Cecilia
De Maio, Ermelinda
Salvadori, Barbara
Marini, Andrea
Pellino, Antonio
Stasi, Irene
Emdin, Michele
Giaconi, Stefano
Marcucci, Lorenzo
Allegrini, Giacomo
CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (08) : 5113 - 5120
[8] Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial
Muss, Hyman B.
Polley, Mei-Yin C.
Berry, Donald A.
Liu, Heshan
Cirrincione, Constance T.
Theodoulou, Maria
Mauer, Ann M.
Kornblith, Alice B.
Partridge, Ann H.
Dressler, Lynn G.
Cohen, Harvey J.
Kartcheske, Patricia A.
Perez, Edith A.
Wolff, Antonio C.
Gralow, Julie R.
Burstein, Harold J.
Mahmood, Ahmad A.
Sutton, Linda M.
Magrinat, Gustav
Parker, Barbara A.
Hart, Ronald D.
Grenier, Debjani
Hurria, Arti
Jatoi, Aminah
Norton, Larry
Hudis, Clifford A.
Winer, Eric P.
Carey, Lisa
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (26) : 2338 - +
[9] A Dose-Escalating Pilot Study (NCT03017404) of Pegylated Liposomal Doxorubicin and Cyclophosphamide, Followed by Docetaxel Administration as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer
Cheng, Meng
Song, Zhenchuan
Qi, Yixin
Wang, Xinle
Zhang, Lina
Shi, Jiajie
Wang, Mingxia
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (05) : 269 - 274
[10] Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older:: Feasibility and tolerability in a subset of patients in a randomized trial
Kümmel, S
Krocker, J
Kohs, A
Breitbach, GP
Morack, G
Budner, M
Blohmer, JU
Lichtenegger, W
Elling, D
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 58 (02) : 166 - 175

← 1 2 3 4 5 →